Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)

Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD.
Supplier Selleck Chemicals
Product # A2712
Sku # A2712-1mg
Pricing 1mg, $539.00
Feedback